Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Inclusion Criteria: * Type 1 diabetes for at least 12 months * Currently on basal bolus treatment with soluble human insulin, Lispro and NPH insulin or Lantus. NPH insulin may be administered once or twice daily * BMI (Body Mass Index) maximum 35 kg/m\^2 * Able and willing to perform self-blood glucose monitoring Exclusion Criteria: * The receipt of any investigational drug within the last 30 days prior to this trial * Total daily insulin dose at least 1.8 U/kg/day * Currently being treated with insulin aspart products * A history of drug abuse or alcohol dependence within the last 5 years * Impaired hepatic function * Impaired renal function * Blood donation (exceeding 500 ml) within the last nine weeks or haemoglobin below the lower reference limit according to the local laboratory * Cardiac problems * Severe, uncontrolled hypertension